1. Home
  2. AZN
  3. AZN News

Latest AstraZeneca PLC (AZN) News on January 20, 2025

Tariff threats, drug pricing will be 2 key pharma issues during Trump's first year
AZN

Yahoo Finance

2 days ago

Tariff threats, drug pricing will be 2 key pharma issues during Trump's first year

Ozempic, Xtandi among next 15 drugs selected for U.S. price talks
AZN

TipRanks

2 days ago

Ozempic, Xtandi among next 15 drugs selected for U.S. price talks

DATROWAY® (datopotamab deruxtecan-dlnk) approved in the US for patients with previously treated metastatic HR-positive, HER2-negative breast cancer
AZN

Business Wire

3 days ago

DATROWAY® (datopotamab deruxtecan-dlnk) approved in the US for patients with previously treated metastatic HR-positive, HER2-negative breast cancer

Medicare to negotiate prices on 15 drugs, including Ozempic
AZN

Yahoo Finance Video

3 days ago

Medicare to negotiate prices on 15 drugs, including Ozempic

Pharma Stock Roundup: J&J's ITCI Buyout, LLY's Weak Q4 Sales
AZN

Zacks

3 days ago

Pharma Stock Roundup: J&J's ITCI Buyout, LLY's Weak Q4 Sales

Novo Nordisk's stock down 4% as the Feds get ready for a second round of drug price negotiations
AZN

Yahoo Finance

3 days ago

Novo Nordisk's stock down 4% as the Feds get ready for a second round of drug price negotiations

AZN

Financial Times

3 days ago

AstraZeneca overhauls management of its scandal-hit China division

AZN

MT Newswires

3 days ago

Astrazeneca Says Mantle Cell Lymphoma Combination Treatment Receives FDA Approval

CALQUENCE® (acalabrutinib) plus chemoimmunotherapy approved in the US for patients with previously untreated mantle cell lymphoma
AZN

Business Wire

3 days ago

CALQUENCE® (acalabrutinib) plus chemoimmunotherapy approved in the US for patients with previously untreated mantle cell lymphoma

COPD market to expand with AstraZeneca’s focus on biologics and strong portfolio growth
AZN

Pharmaceutical Technology

3 days ago

COPD market to expand with AstraZeneca’s focus on biologics and strong portfolio growth

AZN

MT Newswires

5 days ago

Cellectis Files for Resale of 44 Million Company Shares by AstraZeneca

JP Morgan 2025: AstraZeneca promises a ‘catalyst-rich’ year ahead
AZN

Pharmaceutical Technology

5 days ago

JP Morgan 2025: AstraZeneca promises a ‘catalyst-rich’ year ahead

3 High-Yielding Dividend Stocks That Are Trading at Dirt Cheap Prices
AZN

Motley Fool

6 days ago

3 High-Yielding Dividend Stocks That Are Trading at Dirt Cheap Prices

Is AstraZeneca (AZN) Top Stock Pick in Billionaire George Soros’ Portfolio?
AZN

Insider Monkey

6 days ago

Is AstraZeneca (AZN) Top Stock Pick in Billionaire George Soros’ Portfolio?

Why Astrazeneca (AZN) is a Top Value Stock for the Long-Term
AZN

Zacks

7 days ago

Why Astrazeneca (AZN) is a Top Value Stock for the Long-Term

AZN

MT Newswires

7 days ago

Astrazeneca Receives Priority Review for Datopotamab Deruxtecan in Non-Small Cell Lung Cancer

Datopotamab deruxtecan granted Priority Review in the US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer
AZN

Business Wire

7 days ago

Datopotamab deruxtecan granted Priority Review in the US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer

3 Cheap Growth Stocks to Buy in 2025
AZN

Motley Fool

11 days ago

3 Cheap Growth Stocks to Buy in 2025

Astrazeneca (AZN) Stock Falls Amid Market Uptick: What Investors Need to Know
AZN

Zacks

12 days ago

Astrazeneca (AZN) Stock Falls Amid Market Uptick: What Investors Need to Know

Why Astrazeneca (AZN) is a Top Growth Stock for the Long-Term
AZN

Zacks

12 days ago

Why Astrazeneca (AZN) is a Top Growth Stock for the Long-Term

J&J says cancer drug combination showed survival benefit over Tagrisso
AZN

BioPharma Dive

13 days ago

J&J says cancer drug combination showed survival benefit over Tagrisso

Why Is AstraZeneca PLC (NASDAQ:AZN) Among the Best FTSE Dividend Stocks to Buy Now?
AZN

Insider Monkey

14 days ago

Why Is AstraZeneca PLC (NASDAQ:AZN) Among the Best FTSE Dividend Stocks to Buy Now?

AstraZeneca Stock Down Almost 14% in 3 Months: Time to Sell?
AZN

Zacks

14 days ago

AstraZeneca Stock Down Almost 14% in 3 Months: Time to Sell?

AZN

Argus Research

14 days ago

Weekly Stock List

Better Buy: Novo Nordisk vs. AstraZeneca
AZN

Motley Fool

16 days ago

Better Buy: Novo Nordisk vs. AstraZeneca

China’s NMPA prioritises HUTCHMED’s lung cancer therapy review
AZN

Pharmaceutical Technology

18 days ago

China’s NMPA prioritises HUTCHMED’s lung cancer therapy review

The Zacks Analyst Blog Eli Lilly, J&J, AbbVie, AstraZeneca and Pfizer
AZN

Zacks

18 days ago

The Zacks Analyst Blog Eli Lilly, J&J, AbbVie, AstraZeneca and Pfizer

MNPR Stock Skyrockets 384% in 3 Months After Deal With AZN
AZN

Zacks

18 days ago

MNPR Stock Skyrockets 384% in 3 Months After Deal With AZN

5 Large Drug Stocks to Keep An Eye On in the New Year
AZN

Zacks

18 days ago

5 Large Drug Stocks to Keep An Eye On in the New Year

Is AstraZeneca PLC (AZN) Among the U.K. Dividend Champions for 2024?
AZN

Insider Monkey

21 days ago

Is AstraZeneca PLC (AZN) Among the U.K. Dividend Champions for 2024?

Is AstraZeneca PLC (AZN) Among the U.K. Dividend Aristocrats for 2024?
AZN

Insider Monkey

23 days ago

Is AstraZeneca PLC (AZN) Among the U.K. Dividend Aristocrats for 2024?

Astrazeneca (AZN) Stock Moves -0.39%: What You Should Know
AZN

Zacks

24 days ago

Astrazeneca (AZN) Stock Moves -0.39%: What You Should Know

Here's Why Astrazeneca (AZN) is a Strong Value Stock
AZN

Zacks

24 days ago

Here's Why Astrazeneca (AZN) is a Strong Value Stock

AZN, Daiichi Withdraw EU Filing for Dato-DXd in Nonsquamous NSCLC
AZN

Zacks

25 days ago

AZN, Daiichi Withdraw EU Filing for Dato-DXd in Nonsquamous NSCLC

AstraZeneca's (LON:AZN) investors will be pleased with their respectable 55% return over the last five years
AZN

Simply Wall St.

a month ago

AstraZeneca's (LON:AZN) investors will be pleased with their respectable 55% return over the last five years

Achilles Therapeutics sells technology assets to AstraZeneca for $12M
AZN

TipRanks

a month ago

Achilles Therapeutics sells technology assets to AstraZeneca for $12M

AstraZeneca, Daiichi Sankyo have voluntarily withdrawn a Dato-DXd MAA in EU
AZN

TipRanks

a month ago

AstraZeneca, Daiichi Sankyo have voluntarily withdrawn a Dato-DXd MAA in EU

AZN

MT Newswires

a month ago

Achilles Therapeutics Sells Technology Assets to AstraZeneca for $12 Million, Concluding Strategic Review; Shares Up

AZN

MT Newswires

a month ago

AstraZeneca, Daiichi Sankyo Withdraw EU Marketing Application for Lung Cancer Drug Candidate

AstraZeneca’s Tagrisso gains EC approval for NSCLC treatment
AZN

Pharmaceutical Technology

a month ago

AstraZeneca’s Tagrisso gains EC approval for NSCLC treatment

Why Is AstraZeneca PLC (AZN) Among the Best European Dividend Stocks To Buy Now?
AZN

Insider Monkey

a month ago

Why Is AstraZeneca PLC (AZN) Among the Best European Dividend Stocks To Buy Now?

AZN

MT Newswires

a month ago

Astrazeneca's Tagrisso Approved in EU for Lung Cancer

AZN's Tagrisso Gets Approval in the EU for Expanded Use in NSCLC
AZN

Zacks

a month ago

AZN's Tagrisso Gets Approval in the EU for Expanded Use in NSCLC

Is AstraZeneca Stock a Buy?
AZN

Motley Fool

a month ago

Is AstraZeneca Stock a Buy?

Why Astrazeneca (AZN) Outpaced the Stock Market Today
AZN

Zacks

a month ago

Why Astrazeneca (AZN) Outpaced the Stock Market Today

Merck-AstraZeneca breast cancer drug reduces risk of death by 28% in patients diagnosed early, clinical trial shows
AZN

Fortune

a month ago

Merck-AstraZeneca breast cancer drug reduces risk of death by 28% in patients diagnosed early, clinical trial shows

Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
AZN

Zacks

a month ago

Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick

Merck's BLA for RSV Antibody Clesrovimab Gets FDA Acceptance
AZN

Zacks

a month ago

Merck's BLA for RSV Antibody Clesrovimab Gets FDA Acceptance

AZN

MT Newswires

a month ago

Astrazeneca's Alexion Pharma Signs LOI With Pan-Canadian Pharmaceutical Alliance for Koselugo

Alexion, AstraZeneca Rare Disease reaches an agreement with the pan-Canadian Pharmaceutical Alliance (pCPA) for Koselugo (selumetinib) for the treatment of paediatric patients with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN)
AZN

CNW Group

a month ago

Alexion, AstraZeneca Rare Disease reaches an agreement with the pan-Canadian Pharmaceutical Alliance (pCPA) for Koselugo (selumetinib) for the treatment of paediatric patients with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN)

AZN

MT Newswires

a month ago

Market Chatter: AstraZeneca's Sales in China Hit by Arrest of Country Head, Oncology Products Affected

Is AstraZeneca PLC (AZN) the Best Weight Loss Stock to Buy Now According to Hedge Funds?
AZN

Insider Monkey

a month ago

Is AstraZeneca PLC (AZN) the Best Weight Loss Stock to Buy Now According to Hedge Funds?

3 Unstoppable Stocks to Buy Right Now
AZN

Motley Fool

a month ago

3 Unstoppable Stocks to Buy Right Now

Eli Lilly Reports Positive Data From Late-Stage Breast Cancer Study
AZN

Zacks

a month ago

Eli Lilly Reports Positive Data From Late-Stage Breast Cancer Study

AstraZeneca-Merck Partnered Lynparza Shows Long-Term Survival With Reduced Death Risk Of 28% In Breast Cancer Patients
AZN

Benzinga

a month ago

AstraZeneca-Merck Partnered Lynparza Shows Long-Term Survival With Reduced Death Risk Of 28% In Breast Cancer Patients

AZN

MT Newswires

a month ago

AstraZeneca, Merck's Lynparza Shows Prolonged Survival Benefit in Early Breast Cancer Patients

LYNPARZA® (olaparib) demonstrated clinically meaningful prolonged survival benefit in early breast cancer in OlympiA Phase III trial
AZN

Business Wire

a month ago

LYNPARZA® (olaparib) demonstrated clinically meaningful prolonged survival benefit in early breast cancer in OlympiA Phase III trial

AstraZeneca’s (AZN) Struggles: Cramer’s Disappointment and Challenges in China
AZN

Insider Monkey

a month ago

AstraZeneca’s (AZN) Struggles: Cramer’s Disappointment and Challenges in China

AZN, Daiichi's ADC Gets FDA Breakthrough Tag for EGFR-Mutated NSCLC
AZN

Zacks

a month ago

AZN, Daiichi's ADC Gets FDA Breakthrough Tag for EGFR-Mutated NSCLC

Why Astrazeneca (AZN) is a Top Value Stock for the Long-Term
AZN

Zacks

a month ago

Why Astrazeneca (AZN) is a Top Value Stock for the Long-Term

AZN

MT Newswires

a month ago

Astrazeneca Reports Positive Phase 3 Calquence Data for Chronic Lymphocytic Leukemia

AZN's Bladder Cancer sBLA for Imfinzi Gets FDA's Priority Tag
AZN

Zacks

a month ago

AZN's Bladder Cancer sBLA for Imfinzi Gets FDA's Priority Tag

AZN

MT Newswires

a month ago

Astrazeneca, Daiichi Sankyo's Datopotamab Deruxtecan Granted Breakthrough Therapy Designation in US

Datopotamab deruxtecan granted breakthrough therapy designation in US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer
AZN

Business Wire

a month ago

Datopotamab deruxtecan granted breakthrough therapy designation in US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer

ASH 2024: AstraZeneca set to take a BiTE out of follicular lymphoma market
AZN

Clinical Trials Arena

a month ago

ASH 2024: AstraZeneca set to take a BiTE out of follicular lymphoma market

Priority FDA review given to AstraZeneca’s Imfinzi sBLA for MIBC
AZN

Pharmaceutical Technology

a month ago

Priority FDA review given to AstraZeneca’s Imfinzi sBLA for MIBC

Fixed-duration CALQUENCE plus venetoclax demonstrated superior PFS vs. standard of care in previously untreated CLL, with 77% of patients progression free at three years in AMPLIFY Phase III trial
AZN

Business Wire

a month ago

Fixed-duration CALQUENCE plus venetoclax demonstrated superior PFS vs. standard of care in previously untreated CLL, with 77% of patients progression free at three years in AMPLIFY Phase III trial

Insider Stock Buying Reaches US$2.58m On AstraZeneca
AZN

Simply Wall St.

a month ago

Insider Stock Buying Reaches US$2.58m On AstraZeneca

AZN

MT Newswires

a month ago

AstraZeneca's Imfinzi Granted Priority Review in US as Muscle-Invasive Bladder Cancer Treatment

AZN

MT Newswires

a month ago

AstraZeneca Says Dato-DXd Shows 'Clinically Meaningful' Results in Previously Treated Lung Cancer

IMFINZI® (durvalumab) granted Priority Review in the US ​for patients with muscle-invasive bladder cancer
AZN

Business Wire

a month ago

IMFINZI® (durvalumab) granted Priority Review in the US ​for patients with muscle-invasive bladder cancer

AstraZeneca, Daiichi build cancer drug case; Amgen invests $1B
AZN

BioPharma Dive

a month ago

AstraZeneca, Daiichi build cancer drug case; Amgen invests $1B

FDA Approves AstraZeneca's Blockbuster Cancer Drug Imfinzi For Aggressive Form Of Lung Cancer
AZN

Benzinga

2 months ago

FDA Approves AstraZeneca's Blockbuster Cancer Drug Imfinzi For Aggressive Form Of Lung Cancer

AstraZeneca's Imfinzi Gets FDA Nod for Expanded Use in SCLC
AZN

Zacks

2 months ago

AstraZeneca's Imfinzi Gets FDA Nod for Expanded Use in SCLC

Here's Why Astrazeneca (AZN) is a Strong Momentum Stock
AZN

Zacks

2 months ago

Here's Why Astrazeneca (AZN) is a Strong Momentum Stock

Drugmaker AstraZeneca names new China chief to replace detained executive
AZN

CNN Business

2 months ago

Drugmaker AstraZeneca names new China chief to replace detained executive

AZN

MT Newswires

2 months ago

AstraZeneca Says Imfinzi Approved in US for Limited-Stage Small Cell Lung Cancer

IMFINZI® (durvalumab) approved in the US as first and only immunotherapy regimen for patients with limited-stage small cell lung cancer
AZN

Business Wire

2 months ago

IMFINZI® (durvalumab) approved in the US as first and only immunotherapy regimen for patients with limited-stage small cell lung cancer

FDA approves AstraZeneca’s Imfinzi to treat LS-SCLC
AZN

Pharmaceutical Technology

2 months ago

FDA approves AstraZeneca’s Imfinzi to treat LS-SCLC

AstraZeneca Appoints Iskra Reic as International EVP Amid Chinese Investigation; Stock Down 3.8% YTD
AZN

GuruFocus.com

2 months ago

AstraZeneca Appoints Iskra Reic as International EVP Amid Chinese Investigation; Stock Down 3.8% YTD

AZN

Financial Times

2 months ago

AstraZeneca appoints new China head after long-standing executive detained

Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio
AZN

Zacks

2 months ago

Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio

How Alexion markets a rare disease drug by ‘starting with the end in mind’
AZN

Pharma Voice

2 months ago

How Alexion markets a rare disease drug by ‘starting with the end in mind’

Why AstraZeneca PLC (AZN) Is One of the Most Profitable Pharmaceutical Stocks Right Now?
AZN

Insider Monkey

2 months ago

Why AstraZeneca PLC (AZN) Is One of the Most Profitable Pharmaceutical Stocks Right Now?

AZN

Morningstar Research

2 months ago

Analyst Report: AstraZeneca PLC

The Zacks Analyst Blog Highlights Chevron, AstraZeneca and Arista Networks
AZN

Zacks

2 months ago

The Zacks Analyst Blog Highlights Chevron, AstraZeneca and Arista Networks

The Zacks Analyst Blog Highlights Roche, Poseida Therapeutics, Merck, AstraZeneca and Novartis
AZN

Zacks

2 months ago

The Zacks Analyst Blog Highlights Roche, Poseida Therapeutics, Merck, AstraZeneca and Novartis

Why AstraZeneca PLC (AZN) Is One of the Best ADR Stocks to Invest in?
AZN

Insider Monkey

2 months ago

Why AstraZeneca PLC (AZN) Is One of the Best ADR Stocks to Invest in?

Pharma Stock Roundup: RHHBY to Buy PSTX, MRK, AZN See Pipeline Success
AZN

Zacks

2 months ago

Pharma Stock Roundup: RHHBY to Buy PSTX, MRK, AZN See Pipeline Success

Top Stock Reports for Chevron, AstraZeneca & Arista Networks
AZN

Zacks

2 months ago

Top Stock Reports for Chevron, AstraZeneca & Arista Networks

AZN

MT Newswires

2 months ago

Astrazeneca's Enhertu, Orpathys Among 91 Drugs Added to China's National Reimbursement Drug List

Fasenra shows benefit in acute asthma and COPD in Phase II trial
AZN

Clinical Trials Arena

2 months ago

Fasenra shows benefit in acute asthma and COPD in Phase II trial

AstraZeneca's Combination Therapy Meets Goal in Prostate Cancer Study
AZN

Zacks

2 months ago

AstraZeneca's Combination Therapy Meets Goal in Prostate Cancer Study

Failure of AstraZeneca’s AZD4041 a blow for non-opioid OUD treatments
AZN

Clinical Trials Arena

2 months ago

Failure of AstraZeneca’s AZD4041 a blow for non-opioid OUD treatments

AZN

Argus Research

2 months ago

Analyst Report: AstraZeneca PLC

AZN

Argus Research

2 months ago

Market Digest: GOLD, ALL, CHD, LHX, HST, AZN, DOW

AstraZeneca reports results from trial of combination therapy for prostate cancer
AZN

Clinical Trials Arena

2 months ago

AstraZeneca reports results from trial of combination therapy for prostate cancer

AstraZeneca PLC (NASDAQ:AZN) Focuses on Growth in the U.S.: Is It the Best Time to Invest In AZN?
AZN

Insider Monkey

2 months ago

AstraZeneca PLC (NASDAQ:AZN) Focuses on Growth in the U.S.: Is It the Best Time to Invest In AZN?

AZN

MT Newswires

2 months ago

Astrazeneca Potential Metastatic Prostate Cancer Study Shows Early Promise

TRUQAP® (capivasertib) combination in PTEN-deficient metastatic hormone-sensitive prostate cancer demonstrated statistically significant and clinically meaningful improvement in radiographic progression-free survival in CAPItello-281 Phase III trial
AZN

Business Wire

2 months ago

TRUQAP® (capivasertib) combination in PTEN-deficient metastatic hormone-sensitive prostate cancer demonstrated statistically significant and clinically meaningful improvement in radiographic progression-free survival in CAPItello-281 Phase III trial

Share on Social Networks: